April 30, 2026

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

Conexiant

April 30, 2026

Post-Dobbs Mortality Trends Remain Unclear

New study highlights the complex impact of abortion bans on pregnancy-associated mortality, revealing disparities across racial groups and states. Source: JAMA Network Open.

Conexiant

April 30, 2026

AI Didn’t Beat Doctors at Empathy. Medicine Moved Doctors Away From It.

Administrative burden shifted physicians away from direct patient care — AI may help restore it.

Conexiant

April 30, 2026

Medical Oddities: From Romance to Recall Issues

Mental health check: what patients eat, watch, love, and dream may all be in play

Conexiant

April 30, 2026

Urgent Care, Unchecked Power

An unsupervised clinic model and blurred boundaries expose how oversight can fail in outpatient care.

Conexiant

April 29, 2026

FDA Updates Lumateperone Label With Relapse-Prevention Data

Label update incorporates randomized withdrawal trial findings showing delayed time to relapse and consistent safety profile in schizophrenia

Conexiant

April 29, 2026

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

April 29, 2026

Side Effects: The Stuff We Ignore

An anal fissure masquerading as hemorrhoid pain. A spouse's family history predicting your survival. Melatonin labels lying about their own dosage. This week's studies reward the clinician who looks twice.

Conexiant

April 29, 2026

When Documentation Replaces Care

Recent fraud cases show how clinical decision-making, oversight, and reimbursement can drift apart, creating systems where volume outpaces medical necessity.

Conexiant

April 29, 2026

PT vs CBT for Chronic Low Back Pain

Sequential, multiple-assignment randomized trial compares stage I and stage II nonpharmacologic treatments over 52 weeks.

Conexiant